<DOC>
	<DOCNO>NCT00101621</DOCNO>
	<brief_summary>M40403 find effective reduce pain animal model clinical study subject experience pain dental surgery . The propose study design investigate efficacy safety M40403 co-administered opioid subject pain due cancer .</brief_summary>
	<brief_title>Pilot Study Evaluate Safety Analgesic Activity M40403 Co-Administered With Opioid Agent Cancer Pain</brief_title>
	<detailed_description>The propose study design investigate efficacy , safety , pharmacokinetics M40403 subject pain related cancer . Because effect M40403 previously investigate subject cancer-related pain , safety single dose 0.0625 , 0.125 , 0.25 mg/kg M40403 evaluate open label phase study . These dos M40403 similar dos use subject experience pain prior clinical study M40403 .</detailed_description>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Has somatic visceral pain due solid tumor cancer ( adrenal , basal cell , breast cancer ; transitional cell carcinoma bladder uroepithelium ; cholangiocarcinoma ; small intestine/colon/rectal cancer ; adenocarcinoma , esophageal/gastric cancer ; hepatocellular , ovarian , pancreatic , prostate cancer ; bony/soft tissue sarcoma ; small cell lung cancer ; non small cell lung cancer ; adenocarcinoma unknown primary origin ) . Has moderate severe pain measured Pain Intensity Assessment ( categorical scale ) , pain intensity measurement great equal 40 mm visual analog scale ( VAS ) prior morning dose pain medication . Stable chronic cancer pain evidence stable , schedule opioid regimen 7 day prior treatment study medication few 3 rescue dos per day average 3 day prior treatment study medication . Currently take morphine , hydromorphone , oxycodone oxycodone/acetaminophen combination treatment cancer pain . Age 18 old . Performance status 0 2 Eastern Cooperative Oncology Group ( ECOG ) scale . If take concomitant medication , subject steady regimen past 2 week . For female subject : 2 year postmenopausal currently use effective contraception , lactate ; negative urine pregnancy test within 24 hour randomization . Weight 40 90 kg body mass index ( BMI ) 18 32 1week period prior treatment . Able remain facility allow completion pain safety assessment least 8 hour receive study medication . Has significant medical disease malignancy , Investigator ’ opinion , may interfere study participation completion study . Has history chronic analgesic tranquilizer use ( except subject ’ current pain medication [ morphine , hydromorphone , oxycodone , oxycodone/acetaminophen combination ] ) know substance abuse within 90 day prior screen visit . Other drug analgesic property , include nonsteroidal antiinflammatory drug , corticosteroid , tricyclic antidepressant , anticonvulsant , antiarrhythmic , bisphosphonates gabapentinoids initiate study . Patients receive stable dos agent pain management indication &gt; 1 week prior screen visit may continue treatment provide dose remain constant study . Is unwilling abstain alcohol least 8 hour prior dose study medication time discharge study unit . Has receive anticipate receive vitamin mineral supplement 24 hour prior dose time discharge study unit . Has receive investigational medication within 30 day prior administration study medication schedule receive investigational drug study drug course study . Has clinically significant hypersensitivity morphine , oxycodone , hydromorphone , opioids , nonsteroidal antiinflammatory drug ( NSAIDs ) , acetaminophen . Has laboratory abnormality , opinion Investigator , would contraindicate study participation , include aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , blood urea nitrogen ( BUN ) level great equal 1.5 time upper limit normal ( ULN ) creatinine level great ULN screen evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>cancer</keyword>
	<keyword>pain</keyword>
	<keyword>Cancers , Pain</keyword>
</DOC>